Linda Llewelyn Sells 6,442 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,442 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $5.80, for a total transaction of $37,363.60. Following the completion of the transaction, the insider now directly owns 92,260 shares of the company’s stock, valued at approximately $535,108. This trade represents a 6.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Linda Llewelyn also recently made the following trade(s):

• On Monday, December 16th, Linda Llewelyn sold 6,442 shares of Health Catalyst stock. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96.

Health Catalyst Stock Down 0.2 %

Shares of NASDAQ HCAT opened at $5.49 on Friday. Health Catalyst, Inc. has a 1 year low of $5.35 and a 1 year high of $10.99. The firm’s 50 day moving average price is $7.56 and its 200 day moving average price is $7.51. The firm has a market cap of $334.07 million, a P/E ratio of -4.07 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.22) EPS. As a group, sell-side analysts anticipate that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

HCAT has been the subject of a number of research analyst reports. Royal Bank of Canada dropped their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a report on Wednesday. Stephens increased their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a research report on Wednesday, January 8th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target (up from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Health Catalyst presently has a consensus rating of “Moderate Buy” and an average price target of $11.27.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds have recently made changes to their positions in the stock. Harbor Capital Advisors Inc. boosted its holdings in shares of Health Catalyst by 21.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after purchasing an additional 2,064 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Health Catalyst by 10.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after buying an additional 2,164 shares in the last quarter. Creative Planning lifted its holdings in Health Catalyst by 13.2% in the 3rd quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after buying an additional 2,486 shares in the last quarter. Quarry LP lifted its holdings in Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares in the last quarter. Finally, Probity Advisors Inc. raised its stake in shares of Health Catalyst by 13.3% in the 3rd quarter. Probity Advisors Inc. now owns 23,045 shares of the company’s stock valued at $188,000 after purchasing an additional 2,699 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.